Core Insights - The DIAMOND study presents a new approach to nasopharyngeal carcinoma treatment by demonstrating that a full-course immunotherapy regimen can achieve comparable efficacy to traditional chemotherapy while significantly reducing toxic side effects [1][4][6] Group 1: Study Overview - The DIAMOND study involved 532 patients with locally advanced nasopharyngeal carcinoma, utilizing a 1:1 randomization to compare a treatment group receiving immunotherapy and a control group receiving additional chemotherapy [4] - The primary endpoints were the three-year failure-free survival (FFS) rate and the incidence of all-grade vomiting [4][5] Group 2: Results and Efficacy - The treatment group achieved a three-year FFS rate of 88.3%, compared to 87.6% in the control group, indicating that omitting concurrent cisplatin does not compromise survival rates [4][5] - The incidence of all-grade vomiting was significantly lower in the treatment group at 26.2%, compared to 59.8% in the control group, representing a 33.6% reduction (p<0.001) [4][5] Group 3: Safety and Tolerability - The severe acute toxicity rates (grades 3-4) were 52.3% in the treatment group versus 63.6% in the control group, showing an 11.3% decrease in severe side effects [4][5] - The findings suggest that the new treatment regimen enhances patient safety and quality of life by reducing the toxic effects associated with traditional chemotherapy [5][6]